{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-000820","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2022-07-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.500971+00:00","generated_at":"2026-06-24T21:09:06.346239+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"USANA preliminary Q2 net sales ~$265M (down 21% YoY); cuts FY2022 guidance sharply","bullets":["Preliminary Q2 net sales ~$265M vs $337M a year ago; EPS ~$1.05 vs $1.87.","FY2022 guidance cut: net sales now $1.015-1.065B (prev. $1.1-1.2B); EPS $3.85-4.45 (prev. $5.00-5.70).","COVID lockdowns in China and regional sales program disruption drove weaker Q2 results.","CEO Kevin Guest cites lower program participation and inflationary pressures; final Q2 results due July 26."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-000820","json":"https://secwatch.observer/filing/0001157523-22-000820.json","markdown":"https://secwatch.observer/filing/0001157523-22-000820.md","text":"https://secwatch.observer/filing/0001157523-22-000820.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000115752322000820/0001157523-22-000820-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000115752322000820/a52772859.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T21:09:06.346239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}